The reduced tumor volume after treatment with mTOR inhibitors was already shown in in GEO (KRASG12A; both OSI027 and Rapamycin), SW480 (KRASG12V; Rapamycin), LS174T (KRASG12D; Rapamycin) and HT29 (BRAFV600E) xenografts42–44. This evidence concerns the gene MTOR and neoplasm.